Filing Flows › Rigel Pharmaceuticals (RIGL) › How it makes money
How Rigel Pharmaceuticals (RIGL) makes money
Rigel Pharmaceuticals (RIGL) made $80.9M of revenue in the third quarter 2026 (Q3 2026), +16% from a year earlier. Product sales, net brought in $72.3M (89%); Contract revenues from collaborations and other brought in $8.6M (11%). Of every dollar of revenue, 21¢ was left as operating profit, 16¢ was left as net earnings.
Drawing the Sankey…
Revenue by segment, Q3 2026
| Segment | Revenue | Share | Q/Q | Y/Y |
|---|---|---|---|---|
| Product sales, net | $72.3M | 89.4% | +8% | +13% |
| Contract revenues from collaborations and other | $8.6M | 10.6% | -26% | +59% |
Where each dollar of revenue goes
| Line | Q3 2026 | % of revenue |
|---|---|---|
| Revenue | $80.9M | 100.0% |
| Operating profit | $17.1M | 21.1% |
| Income tax | $4.2M | 5.2% |
| Net earnings | $13.2M | 16.3% |
| Operating cash flow | $34.6M | 42.7% |
Revenue, quarter by quarter
| Quarter | Revenue | Y/Y |
|---|---|---|
| Q3 2026 | $80.9M | +16% |
| Q2 2026 | $78.7M | -23% |
| Q1 2026 | $58.8M | +10% |
| Q4 2025 | $69.8M | +21% |
| Q3 2025 | $69.5M | +26% |
| Q2 2025 | $102M | +176% |
| Q1 2025 | $53.3M | +81% |
From Rigel Pharmaceuticals' 10-Q filed Nov 5, 2026 (on EDGAR).
Questions
How does Rigel Pharmaceuticals make money?
Rigel Pharmaceuticals (RIGL) made $80.9M of revenue in the third quarter 2026 (Q3 2026), +16% from a year earlier. Product sales, net brought in $72.3M (89%); Contract revenues from collaborations and other brought in $8.6M (11%). Of every dollar of revenue, 21¢ was left as operating profit, 16¢ was left as net earnings.
What is Rigel Pharmaceuticals' biggest business?
Product sales, net: $72.3M in the third quarter 2026, 89% of revenue, +13% from a year earlier.
What is Rigel Pharmaceuticals' profit margin?
Net earnings were $13.2M, 16.3% of revenue, in the third quarter 2026; the operating margin was 21.1%.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.